High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients

NCT03494270 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

270

Enrollment

INDUSTRY

Sponsor class

Conditions

ASCVD

Interventions

DRUG: Rosuvamibe
DRUG: Monorova

Sponsor

Yuhan Corporation